Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: Assessment of effects on cognitive functions and general status of patients

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 196-202

  Piotrowska, Ewa ^a   Jakobkiewicz Banecka, Joanna ^a   Maryniak, Agnieszka ^b   Tylki Szymanska, Anna ^b   Puk, Ewa ^c   Liberek, Anna ^d   Wegrzyn, Alicja ^a   Czartoryska, Barbara ^e   Slominska Wojewodzka, Monika ^a   Wȩgrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c Biofarm   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Behavioral problems; Genistein; Mucopolysaccharidosis; Substrate reduction therapy

Indexed keywords

GENISTEIN; GENISTEIN RICH SOY ISOFLAVONE EXTRACT; ISOFLAVONE; SOYFEM; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR; CHILD; CLINICAL ARTICLE; COGNITION; FEMALE; FOLLOW UP; HUMAN; MALE; PRESCHOOL CHILD; PSYCHOLOGIC TEST; QUESTIONNAIRE; SANFILIPPO SYNDROME; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 79953703689     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881715     Document Type: Article

References (31)

1. Beck M: Therapy for lysosomal storage disorders. IUBMB Life, 2010; 62: 33-40
2. Neufeld EF, Muenzer J: The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Co, New York, 2001; 3421-52
3. We{ogonek}grzyn G, We{ogonek}grzyn A, Tylki-Szymańska A: A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypoth, 2004; 62: 986-92
4. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A et al: Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr, 2009; 98: 743-49
5. Valstar MJ, Ruijter GJ, van Diggelen OP et al: Sanfilippo syndrome: a mini-review. J Inherit Metab Dis, 2008; 31: 240-52
6. Rohrbach M, Clarke JT: Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs, 2007; 67: 2697-16
7. Cox TM: Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl, 2005; 94: 69-75
8. Jakóbkiewicz-Banecka J, Piotrowska E, Narajczyk M et al: Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci, 2009; 16: 26
9. Roberts AL, Thomas BJ, Wilkinson AS et al: Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res, 2006; 60: 309-14
10. Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S et al: Genisteinmediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet, 2006; 14(7): 846-52
11. Dziedzic D, We{ogonek}grzyn G, Jakóbkiewicz-Banecka J: Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet, 2010; 18: 200-205
12. Kaidonis X, Liaw WC, Roberts AD et al: Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulfate storing mucopolysaccharidoses. Eur J Hum Genet, 2010; 18(2): 194-99
13. Roberts AL, Rees MH, Klebe S et al: Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab, 2007; 92: 115-21
14. Malinowska M, Wilkinson FL, Langford-Smith KJ et al: Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE, 2010; 5(12): e14192
15. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A et al: Genistinrich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp, 2008; 69: 166-79
16. Jakóbkiewicz-Banecka J, We{ogonek}grzyn A, We{ogonek}grzyn G: Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet, 2007; 48: 383-88
17. Wraith JE: The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother, 2005; 6: 489-506
18. Hamano K, Hayashi M, Shioda K et al: Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol, 2007; 115: 547-59
19. Villani GR, Gargiulo N, Faraonio R et al: Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res, 2007; 85: 612-22
20. Villani GR, Di Domenico C, Musella A et al: Mucopolysaccharidosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res, 2009; 1279: 99-108
21. Ohmi K, Kudo LC, Ryazantsev S et al: Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc Natl Acad Sci USA, 2009; 106: 8332-37
22. Liang HW, Qiu SF, Shen J et al: Genistein attenuates oxidative stress and neuronal damage following transient global cerebral ischemia in rat hippocampus. Neurosci Lett, 2008; 438: 116-20
23. Bang OH, Hong HS, Kim DH et al: Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol Dis, 2004; 16: 21-28
24. Zeng H, Chen Q, Zhao B: Genistein ameliorates b-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radical Biol Med, 2004; 36: 180-88
25. Kajta M, Domin H, Grynkiewicz G, Lason W: Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: an involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3b intracellular signaling pathway. Neuroscience, 2007; 145: 592-604
26. Valles SL, Dolz-Gaiton P, Gambini J et al: Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPARg expression in cultured astrocytes. Brain Res, 2010; 1312: 138-44
27. Marotta F, Mao GS, Liu T et al: Anti-inflammatory and neuroprotective effect of a phytoestrogen compound on rat microglia. Ann N Y Acad Sci, 2006; 1089: 276-81
28. Friso A, Tomanin R, Salvalaio M, Scarpa M: Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol, 2010; 159: 1082-91
29. Lisik MZ, Sieron AL: X-linked mental retardation. Med Sci Monit, 2008; 14(11): RA221-29
30. Nester MJ: Use of a brief assessment examination in a study of subacute sclerosing panencephalitis. J Child Neurol, 1996; 11: 173-80
31. Campbell C, Levin S, Humphreys P et al: Subacute sclerosing panencephalitis: results of the Canadian paediatric surveillance program and review of the literature. BMC Pediatr, 2005; 5: 47